Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 23 2021 - 7:54AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to
Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of March, 2021
Commission File Number: 001-37353
BIONDVAX PHARMACEUTICALS LTD.
(Translation of registrant’s name into
English)
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On March 23, 2021,
Mr. Amir Reichman, the Chief Executive Officer of BiondVax Pharmaceuticals Ltd., issued a letter to shareholders.
Exhibit Index
Paragraphs 4 and 5 and the Forward Looking
Statements of Exhibit 99.1 are hereby incorporated by reference into the Company's Registration Statement on Form F-3 (Registration
No. 333-240189) and its Registration Statement on Form S-8 (Registration No. 333-239344).
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
BiondVax Pharmaceuticals Ltd.
|
|
|
|
|
|
Date: March 23, 2021
|
By:
|
/s/ Amir Reichman
|
|
|
|
Amir Reichman
|
|
|
|
Chief Executive Officer
|
3
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Apr 2023 to Apr 2024
